LLY vs MRK
By Alex · Tickerpine
Eli Lilly and Company vs Merck & Co., Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | MRK |
|---|---|---|
| Price | $1,273.46 | $145.27 |
| Market cap | $1.14T | $358.41B |
| P/E ratio | 42.7 | 117.2 |
| ROE | 102.29% | 6.96% |
| Profit margin | 33.53% | 4.77% |
| Revenue growth | 47.70% | 5.10% |
| Dividend yield | 0.54% | 2.34% |
| Beta | 0.45 | 0.22 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs MRK in plain English
- LLY is the bigger company — about 3.2× the market cap of MRK.
- LLY is cheaper on earnings (P/E 42.7 vs 117.2).
- LLY earns a higher return on equity (102% vs 7%).
- LLY is growing revenue faster (48% vs 5%).
- MRK has the higher dividend yield (2.34% vs 0.54%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.